KOC
BEAM icon

Koss-Olinger Consulting’s Beam Therapeutics BEAM Stock Holding History

Koss-Olinger Consulting’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,000
Closed -$1.93M – 239
2021
Q2 		$1.93M Hold
15,000
– – 0.29% 40
2021
Q1 		$1.2M Buy
+15,000
New +$1.43M 0.2% 54

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Koss-Olinger Consulting's BEAM Position: Q3 2021 in Review

Koss-Olinger Consulting sold out of Beam Therapeutics (BEAM) in Q3 2021, closing a stake of 15,000 shares — an estimated $1.93M sold.

Koss-Olinger Consulting first reported a position in BEAM in Q1 2021 and held it in 2 quarters. The position peaked at $1.93M in Q2 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q3 2021.

  • Koss-Olinger Consulting reported no remaining Beam Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Koss-Olinger Consulting sold 15,000 Beam Therapeutics shares in Q3 2021, an estimated $1.93M.
  • Koss-Olinger Consulting first reported a position in Beam Therapeutics in Q1 2021 and held it in 2 quarters.
  • Koss-Olinger Consulting's Beam Therapeutics position peaked at $1.93M in Q2 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2021.

Based on Koss-Olinger Consulting's 13F filing for Q3 2021, filed 9 Nov 2021.